Liquid Biopsy for Cancer Diagnostics Market Report 2026

The liquid biopsy for cancer diagnostics market size has grown rapidly in recent years. It will grow from $10.75 billion in 2025 to $12.52 billion in 2026 at a compound annual growth rate (CAGR) of 16.4%. The growth in the historic period can be attributed to limitations of tissue biopsy procedures, increasing incidence of lung and breast cancer, early adoption of molecular cancer diagnostics, growing need for early-stage cancer detection, rising clinical research in oncology diagnostics.

The liquid biopsy for cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $22.99 billion in 2030 at a compound annual growth rate (CAGR) of 16.4%. The growth in the forecast period can be attributed to expansion of liquid biopsy in routine cancer screening, growing focus on personalized cancer care, increasing adoption in treatment response monitoring, rising investments in cancer diagnostics, expanding use in gastrointestinal and ovarian cancers. Major trends in the forecast period include growing adoption of liquid biopsy in lung cancer diagnosis, rising use of blood-based cancer screening methods, increasing demand for real-time cancer monitoring, expansion of liquid biopsy across multiple cancer types, rising clinical preference for minimally invasive diagnostics.

The increasing incidence of cancer is expected to drive the growth of the liquid biopsy for cancer diagnostics market in the coming years. Cancer is a broad group of diseases that can arise in almost any organ or tissue when abnormal cells grow uncontrollably, breach their normal boundaries, and either spread to other organs or invade surrounding tissues. The prevalence of cancer fuels the demand for diagnostic procedures such as early detection of cancer or tumor recurrence, patient-specific risk assessment, and therapy monitoring, allowing liquid biopsy to capture the complete picture of the disease as tumor cells or tumor cell products are released from all primary or metastatic tumor sites, providing comprehensive and real-time insights into tumor cell progression, therapeutic targets, and mechanisms of treatment resistance. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported approximately 18.1 million cancer survivors in the United States. This number is expected to increase to 22.5 million by 2032. By 2040, the annual number of new cancer cases is projected to reach 29.9 million, with cancer-related deaths estimated to rise to 15.3 million. Thus, the growing incidence of cancer is driving the expansion of the liquid biopsy for cancer diagnostics market.

Major companies operating in the liquid biopsy for cancer diagnostics market are focusing on developing innovative solutions such as advanced liquid biopsy assays. An advanced liquid biopsy assay is a sophisticated diagnostic test that examines various components in a liquid biological sample, such as blood or other bodily fluids, to identify and characterize specific biomarkers linked to cancer or other diseases. For example, in November 2023, Illumina Inc., a US-based global leader in DNA sequencing, announced the launch of ‘TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2)’. This research assay is designed to enable noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) extracted from blood. The TSO 500 ctDNA v2 assay aims to simplify user integration and provide deeper insights for cancer research.

In February 2024, Veracyte Inc., a US-based diagnostics company, acquired C2i Genomics Inc. for approximately US$70 million. Through this acquisition, Veracyte seeks to strengthen its cancer-diagnostics platform by incorporating C2i’s whole-genome minimal residual disease (MRD) detection technology, expanding its capabilities across the cancer-care continuum, enhancing early detection and recurrence monitoring, and offering more detailed insights for clinicians and patients. C2i Genomics Inc. is a US-based biotechnology company specializing in AI-enabled whole-genome MRD testing.

Major companies operating in the liquid biopsy for cancer diagnostics market are F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC.

North America was the largest region in the liquid biopsy for cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liquid biopsy for cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the liquid biopsy for cancer diagnostics market by increasing costs associated with imported detection kits, bioinformatics tools, and advanced laboratory equipment. These impacts are most visible across ctDNA and CTC detection kits and diagnostic services, particularly in regions such as asia-pacific and europe that depend on global diagnostic supply chains. Hospitals and diagnostic centers face higher testing costs and procurement challenges due to tariff pressures. However, tariffs have also encouraged local kit manufacturing, regional service expansion, and diversification of diagnostic supply chains, supporting long-term market stability.

The liquid biopsy for cancer diagnostics market research report is one of a series of new reports that provides liquid biopsy for cancer diagnostics market statistics, including liquid biopsy for cancer diagnostics industry global market size, regional shares, competitors with a liquid biopsy for cancer diagnostics market share, detailed liquid biopsy for cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the liquid biopsy for cancer diagnostics industry. This liquid biopsy for cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Liquid biopsy for cancer diagnostics is a minimally invasive approach compared to traditional tissue biopsies, involving the analysis of genetic material or biomarkers found in a patient’s blood or other bodily fluids to detect and monitor cancer. It is frequently used for screening and detecting non-small cell lung cancer (NSCLC) as well as gastrointestinal and ovarian cancers.

The main types of liquid biopsy for cancer diagnostics include products and services. A product refers to any procedure, method, or tool developed or used to detect a disease or illness in humans or other vertebrate animals. Various types of samples are utilized, such as blood, urine, and saliva. The different types of cancer include lung cancer, breast cancer, colon cancer, and others, and these are used by various end-users, including hospitals, diagnostic centers, and others.

The liquid biopsy for cancer diagnostics market includes revenues earned by entities by providing tumor detection, test validation, and clinical utility. The market value includes the value of related goods sold by the service provider or included within the service offering. The liquid biopsy for cancer diagnostics markets also includes sales of instruments, reagent kits, and liquid biopsy kits, which are used in providing liquid biopsy services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.